USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
21 Jul 2021 | 02:30 PM GMT

DTx - overview of market and deals

Anchored by:

Alexander Hoffmann
General Partner
FORBION

Participants:

Alexander Hoffmann General PartnerForbion
Alexander Hoffmann
General PartnerForbion
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Louis Payet CEOPeach Health
Louis Payet
CEOPeach Health
Maite Malet Investment & Corporate DevelopmentAsabys Partners
Maite Malet
Investment & Corporate DevelopmentAsabys Partners
Prayat Shah Co-Founder, VP, Partnerships & AlliancesWellthy Therapeutics
Prayat Shah
Co-Founder, VP, Partnerships & AlliancesWellthy Therapeutics

About this Meeting

The DTx market is estimated to be worth between 7 and 9 billion US dollars in the next 5 to 7 years and Prescription Digital Therapeutics [PDT] is expected to be the future of the DTx industry, representing 57% of total DTx investment in 2020. In this informal peer-to-peer conversation we will talk about: 
 
  •  The most remarkable investments and partnerships so far in the DTx industry and what is expected to happen in the next few months/years. 
  •  What traits partners and investors expect from DTx companies (e.g clinical evidence, scalability, prescribable and reimbursed solutions, etc) and KPIs to determine if an investment or a partnership is going to be successful. 
  •  The most promising companies in the DTx landscape. 
  •  How will the market evolve to have more integrated solutions? Role of DTx companies mergers, acquisitions?